000 04472naa a22005417i 4500
001 UMUN-OA-20261005-PH-059
003 local
005 20261005174916.0
006 m o d
007 cr||||||||||||
008 261005s2018 xx o u000 0 eng d
024 7 _a10.3748/wjg.v24.i43.4846
_2doi
035 _a(local)EuropePMC:PMC6250924
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aAndrew McGuigan
_eauthor.
245 1 0 _aPancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. /
_cAndrew McGuigan; Paul Kelly; Richard C Turkington [and others].
264 1 _a[Place of publication not identified] :
_bBaishideng Publishing Group Inc,
_c2018.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aThis review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further research in this understudied malignancy. Pancreatic adenocarcinoma is a lethal condition with a rising incidence, predicted to become the second leading cause of cancer death in some regions. It often presents at an advanced stage, which contributes to poor five-year survival rates of 2%-9%, ranking firmly last amongst all cancer sites in terms of prognostic outcomes for patients. Better understanding of the risk factors and symptoms associated with this disease is essential to inform both health professionals and the general population of potential preventive and/or early detection measures. The identification of high-risk patients who could benefit from screening to detect pre-malignant conditions such as pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms is urgently required, however an acceptable screening test has yet to be identified. The management of pancreatic adenocarcinoma is evolving, with the introduction of new surgical techniques and medical therapies such as laparoscopic techniques and neo-adjuvant chemoradiotherapy, however this has only led to modest improvements in outcomes. The identification of novel biomarkers is desirable to move towards a precision medicine era, where pancreatic cancer therapy can be tailored to the individual patient, while unnecessary treatments that have negative consequences on quality of life could be prevented for others. Research efforts must also focus on the development of new agents and delivery systems. Overall, considerable progress is required to reduce the burden associated with pancreatic cancer. Recent, renewed efforts to fund large consortia and research into pancreatic adenocarcinoma are welcomed, but further streams will be necessary to facilitate the momentum needed to bring breakthroughs seen for other cancer sites.
540 _aCreative Commons Attribution-NonCommercial (licence family recorded by the source; version not supplied in metadata).
_uhttps://europepmc.org/articles/PMC6250924
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Public Health.
650 4 _aPancreatic cancer
650 4 _aPancreatic adenocarcinoma
650 4 _aPancreatic Cancer Treatment
650 4 _aPancreatic Cancer Risk Factors
653 _aB. Sc. Public Health
653 _aUMUN open access collection
653 _aepidemiology
655 4 _aReview articles.
700 0 _aPaul Kelly
_eauthor.
700 0 _aRichard C Turkington
_eauthor.
700 0 _aClaire Jones
_eauthor.
700 0 _aHelen G Coleman
_eauthor.
700 0 _aR Stephen McCain
_eauthor.
773 0 _tWorld journal of gastroenterology
_gVol. 24, no. 43, (2018), pages/article 4846-4861
_x1007-9327
856 4 0 _uhttps://europepmc.org/articles/PMC6250924
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC6250924
_qlocal
942 _n0
999 _c1331
_d1331